Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Open For Business: Sandoz’s Austrian Antibiotic Facility Is Ready To Serve

Production Capacity Of Packages Per Year Will Increase By 20%

Executive Summary

As Sandoz continues to fight against antimicrobial resistance, the firm opens a new production facility in Austria, strengthening its position in Europe with a vertically integrated production network for penicillin.

You may also be interested in...



AMR Alliance Follows Up Global Industry Standard With Responsible Manufacturing Certification

A new voluntary certification from the AMR Industry Alliance and the British Standards Institution will assess pharmaceutical firms’ responsibility and sustainability when it comes to manufacturing antibiotic drugs, in an attempt to control the spread of antimicrobial resistance.

Sandoz Eyes First-To-Market US Opportunities With Adalvo Deal

Sandoz has struck a deal with Adalvo that will give the company rights to six products in the US – four of which are potential first-to-market opportunities – targeting markets that are collectively worth around $3bn.

Sandoz Pushes Back On AMR And ‘Dysfunctional’ Antibiotics Market

Sandoz CEO Richard Saynor and global head of anti-infectives Ian Ball have spoken out on the threat of antimicrobial resistance and the “increasing dysfunctionality” of the market framework for antibiotics.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel